Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
Peter Schäfer
Biochemical Pharmacology (2012) Vol. 83, Iss. 12, pp. 1583-1590
Closed Access | Times Cited: 395

Showing 1-25 of 395 citing articles:

Psoriasis
Jacqueline Greb, Ari M. Goldminz, James T. Elder, et al.
Nature Reviews Disease Primers (2016) Vol. 2, Iss. 1
Open Access | Times Cited: 741
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp, Kristian Reich, Craig L. Leonardi, et al.
Journal of the American Academy of Dermatology (2015) Vol. 73, Iss. 1, pp. 37-49
Open Access | Times Cited: 598
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Heng Li, Jianping Zuo, Wei Tang
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 449
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul, Jennifer Clay Cather, Melinda Gooderham, et al.
British Journal of Dermatology (2015) Vol. 173, Iss. 6, pp. 1387-1399
Open Access | Times Cited: 436
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, et al.
Annals of the Rheumatic Diseases (2014) Vol. 73, Iss. 6, pp. 1020-1026
Open Access | Times Cited: 425
Pathogenesis of psoriasis and development of treatment
Eisaku Ogawa, Yuki Sato, Akane Minagawa, et al.
The Journal of Dermatology (2017) Vol. 45, Iss. 3, pp. 264-272
Open Access | Times Cited: 417
The sympathetic nervous response in inflammation
Georg Pongratz, Rainer H. Straub
Arthritis Research & Therapy (2014) Vol. 16, Iss. 6
Open Access | Times Cited: 347
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
Peter Schäfer, Anastasia Parton, Lori Capone, et al.
Cellular Signalling (2014) Vol. 26, Iss. 9, pp. 2016-2029
Open Access | Times Cited: 278
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, et al.
Annals of the Rheumatic Diseases (2016) Vol. 75, Iss. 6, pp. 1065-1073
Open Access | Times Cited: 261
Naturally derived anti-inflammatory compounds from Chinese medicinal plants
Qiuhong Wang, Haixue Kuang, Yang Su, et al.
Journal of Ethnopharmacology (2012) Vol. 146, Iss. 1, pp. 9-39
Closed Access | Times Cited: 217
Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing
Mayte Suárez‐Fariñas, Benjamin Ungar, Shinji Noda, et al.
Journal of Allergy and Clinical Immunology (2015) Vol. 136, Iss. 5, pp. 1277-1287
Closed Access | Times Cited: 214
The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis
Michael P. Schön, Luise Erpenbeck
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 212
Update on psoriasis immunopathogenesis and targeted immunotherapy
Satveer K. Mahil, Francesca Capon, Juliet N. Barker
Seminars in Immunopathology (2015) Vol. 38, Iss. 1, pp. 11-27
Open Access | Times Cited: 211
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
Kristian Reich, Melinda Gooderham, L. Green, et al.
Journal of the European Academy of Dermatology and Venereology (2016) Vol. 31, Iss. 3, pp. 507-517
Open Access | Times Cited: 182
Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome
Gülen Hatemi, Alfred Mahr, Yoshiaki Ishigatsubo, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 20, pp. 1918-1928
Open Access | Times Cited: 166
Phenols in Pharmaceuticals: Analysis of a Recurring Motif
Kevin A. Scott, Philip B. Cox, Jón T. Njardarson
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 10, pp. 7044-7072
Closed Access | Times Cited: 122
New Therapeutics for Ulcerative Colitis
Robert Hirten, Bruce E. Sands
Annual Review of Medicine (2021) Vol. 72, Iss. 1, pp. 199-213
Closed Access | Times Cited: 109
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 76
The translational revolution and use of biologics in patients with inflammatory skin diseases
Shinji Noda, James G. Krueger, Emma Guttman‐Yassky
Journal of Allergy and Clinical Immunology (2014) Vol. 135, Iss. 2, pp. 324-336
Open Access | Times Cited: 187
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
Gillian M. Keating
Drugs (2017) Vol. 77, Iss. 4, pp. 459-472
Closed Access | Times Cited: 166
Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells – Role of Anchored Protein Kinase A Signaling Units
Vanessa L. Wehbi, Kjetil Taskén
Frontiers in Immunology (2016) Vol. 7
Open Access | Times Cited: 165
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
Phoebe Rich, Melinda Gooderham, H. Bachelez, et al.
Journal of the American Academy of Dermatology (2015) Vol. 74, Iss. 1, pp. 134-142
Open Access | Times Cited: 152
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, et al.
The Journal of Rheumatology (2015) Vol. 42, Iss. 3, pp. 479-488
Open Access | Times Cited: 129
Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases
Miriam Wittmann, Philip Helliwell
Dermatology and Therapy (2013) Vol. 3, Iss. 1, pp. 1-15
Open Access | Times Cited: 120
Psoriasis in those planning a family, pregnant or breast‐feeding. The Australasian Psoriasis Collaboration
Marius Rademaker, Karen Agnew, Megan Andrews, et al.
Australasian Journal of Dermatology (2017) Vol. 59, Iss. 2, pp. 86-100
Open Access | Times Cited: 110
Page 1 - Next Page

Scroll to top